|
EP3736574A1
|
|
A formulation comprising an isotope labeled fusion polypeptide
|
|
SG11201906689SA
|
|
Method for determining levels of interactions between biomolecules
|
|
EP3109639A1
|
|
Mass spectrometry quantification
|
|
EP3023791A1
|
|
Predicting the responsiveness to gemcitabine treatment
|
|
EP2787350A1
|
|
ASRGL1 in endometrial cancer
|
|
EP2746768A1
|
|
Podxl in bladder cancer
|
|
EP2602622A1
|
|
Prediction of response to platinum-based therapy
|
|
EP2573566A1
|
|
RBM3 in prostate cancer prognostics
|
|
EP2544007A1
|
|
Biomarker of renal impairment
|
|
EP2524928A1
|
|
RBM3 in bladder cancer
|
|
EP2390665A1
|
|
Prostate cancer biomarkers
|
|
WO2010086400A1
|
|
Combination treatment of breast cancer
|
|
EP2315028A1
|
|
PODXL protein in colorectal cancer
|
|
EP2293070A1
|
|
Means and methods for ovarian cancer prognosis
|
|
EP2446269A1
|
|
Improvement of immunodetectability
|
|
EP2259059A1
|
|
Means and methods for ovarian cancer prognosis
|
|
EP2241889A1
|
|
RBM3 protein in colorectal cancer prognostics
|
|
EP2288721A1
|
|
Treatment prediction involving hmgcr protein
|
|
EP2172477A1
|
|
Epitopes derived from SATB2 and uses thereof
|
|
EP2161577A1
|
|
ANLN protein
|
